This Seminar presents the current best practice for the diagnosis and management of
bladder cancer. The scope of this Seminar ranges from current challenges in pathology …

Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

Bladder cancer is among the ten most common cancers globally, causes considerable
morbidity and mortality and is, therefore, a substantial burden for health-care systems. The …

Urothelial carcinoma (UC), also described as bladder cancer, is the 10th most common
cancer type worldwide, with an estimated 549 000 new cases and 200 000 deaths in 2018 …

Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

Cystectomy is a standard treatment for muscle-invasive bladder cancer (MIBC), but it is life-
altering. We initiated a phase 2 study in which patients with MIBC received four cycles of …

Importance Robot-assisted radical cystectomy is being performed with increasing frequency,
but it is unclear whether total intracorporeal surgery improves recovery compared with open …

Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades,
the systemic management of muscle‐invasive and advanced bladder cancer has primarily …

Context This overview presents the updated European Association of Urology (EAU)
guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). Objective To …

Importance Bladder cancer is a common malignancy in women and is the fourth most
common malignancy in men. Bladder cancer ranges from unaggressive and usually …